SELLAS Life Sciences Group Inc (SLS)

[Hoskuld]

I think you are going to see much, much higher because the pooled data from the December 2025 interim look points to tremendous efficacy. 45% of patients were alive when you should not expect more than 20% alive - which means that roughly 70% of the GPS patients are alive. Patients were accrued to the trial over 5 years (the last patient was added 2 years ago) so we are not talking about 5 year survival, but the median overall survival for the BATs group is ~11 months (generous) and the median overall survival for the GPS group has not yet been reached. If allowed to go to completion, I think HR will be less than 0.3.

All of this adds up to GPS being AML standard of care with a label that should expand to include other WT1 expressing cancers like multiple myeloma, NSCLC, ovarian, etc.

I think we will see orders of magnitude of the current share price because GPS (and SLS009) work well.